ECM1-HF-MSCs showed a more significant therapeutic effect on LC than naïve HF-MSCs, which may be mediated most likely by the inhibition of HSC pathological activation via the TGF-β/Smad pathway. The gene discussed is TGFB1; the disease is laryngotracheoesophageal cleft.